Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.6K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.6K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

728
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
728
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

266
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
266
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hybrid zeolitic imidazolate frameworks with catalytically active TO4 building blocks.

Angewandte Chemie (International ed. in English)·2010
Same author

Whiter matter abnormalities in medication-naive subjects with a single short-duration episode of major depressive disorder.

Psychiatry research·2010
Same author

A new comorbidity index: the health-related quality of life comorbidity index.

Journal of clinical epidemiology·2010
Same author

S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer.

International journal of biological sciences·2010
Same author

Nano-sized SnSbAgx alloy anodes prepared by reductive co-precipitation method used as lithium-ion battery materials.

Journal of nanoscience and nanotechnology·2010
Same author

Complementary diffusion tensor imaging study of the corpus callosum in patients with first-episode and chronic schizophrenia.

Journal of psychiatry & neuroscience : JPN·2010

Related Experiment Video

Updated: Jul 8, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.5K

Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges.

Xin Chen1, Ruyue He1, Xinyi Chen1

  • 1Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China.

Frontiers in Pharmacology
|December 11, 2023
PubMed
Summary

Optimizing drug dose and schedule is crucial for clinical trials. Bayesian adaptive designs offer efficient evaluation of multiple regimens, though real-world examples are limited.

Keywords:
adaptive designbayesian methoddosage optimizationdose-schedule regimenearly phase clinical trial

More Related Videos

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

15.8K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.6K

Related Experiment Videos

Last Updated: Jul 8, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.5K
Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

15.8K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.6K

Area of Science:

  • Clinical Pharmacology
  • Biostatistics
  • Oncology

Background:

  • Early-phase clinical trials often have small sample sizes, leading to uncertain dose-schedule regimens for later trials.
  • Novel anti-tumor treatments and combination therapies increase the complexity of dose-schedule optimization.
  • There is a critical need for efficient strategies to determine optimal dose-schedule regimens.

Purpose of the Study:

  • To review critical factors in dose-schedule optimization for clinical trials.
  • To explore innovative Bayesian adaptive designs for evaluating multiple doses and schedules.
  • To identify unresolved issues and future research directions in this field.

Main Methods:

  • Review of literature on dose-schedule optimization strategies.
  • Analysis of Bayesian adaptive designs, including their assumptions, characteristics, and limitations.
  • Discussion of application scenarios and challenges in real-world implementation.

Main Results:

  • Bayesian adaptive designs show potential for efficient simultaneous evaluation of dose-schedule regimens.
  • Real-world implementation examples of these advanced adaptive designs are currently scarce.
  • Key factors, assumptions, characteristics, and limitations of Bayesian adaptive designs are detailed.

Conclusions:

  • Dose-schedule optimization is essential, especially with novel therapies.
  • Bayesian adaptive designs present a promising, efficient approach but require further real-world validation.
  • Further research is needed to address current limitations and expand the application of these designs.